Stock Scorecard
Stock Summary for Penumbra Inc (PEN) - $289.50 as of 12/9/2025 7:14:33 PM EST
Total Score
12 out of 30
Safety Score
48 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PEN
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PEN
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PEN
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PEN
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PEN (48 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 8 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 3 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 2 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for PEN
Financial Details for PEN
Company Overview |
|
|---|---|
| Ticker | PEN |
| Company Name | Penumbra Inc |
| Country | USA |
| Description | Penumbra, Inc. is a pioneering biotechnology-driven medical device company based in Alameda, California, focusing on transformative solutions for neurological and vascular conditions. With a significant footprint across the United States, Europe, Canada, and Australia, the company is dedicated to improving patient outcomes through its cutting-edge therapeutic products. Penumbra's commitment to quality and innovation not only raises the standard of care but also enhances clinician efficiency, establishing it as a key player in the rapidly advancing medical technology sector. |
| Sector Name | HEALTHCARE |
| Industry Name | MEDICAL DEVICES |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/24/2026 |
Stock Price History |
|
| Last Day Price | 289.50 |
| Price 4 Years Ago | 287.32 |
| Last Day Price Updated | 12/9/2025 7:14:33 PM EST |
| Last Day Volume | 523,596 |
| Average Daily Volume | 514,784 |
| 52-Week High | 310.00 |
| 52-Week Low | 221.26 |
| Last Price to 52 Week Low | 30.84% |
Valuation Measures |
|
| Trailing PE | 70.53 |
| Industry PE | 45.59 |
| Sector PE | 52.63 |
| 5-Year Average PE | 119.67 |
| Free Cash Flow Ratio | 35.30 |
| Industry Free Cash Flow Ratio | 27.04 |
| Sector Free Cash Flow Ratio | 28.62 |
| Current Ratio Most Recent Quarter | 6.73 |
| Total Cash Per Share | 8.20 |
| Book Value Per Share Most Recent Quarter | 34.70 |
| Price to Book Ratio | 8.67 |
| Industry Price to Book Ratio | 4.34 |
| Sector Price to Book Ratio | 33.49 |
| Price to Sales Ratio Twelve Trailing Months | 8.66 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.95 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.13 |
| Analyst Buy Ratings | 12 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 39,162,200 |
| Market Capitalization | 11,337,456,900 |
| Institutional Ownership | 98.47% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 56.00% |
| Annual Earnings Growth | -84.59% |
| Reported EPS 12 Trailing Months | 4.18 |
| Reported EPS Past Year | 2.66 |
| Reported EPS Prior Year | 2.87 |
| Net Income Twelve Trailing Months | 164,027,000 |
| Net Income Past Year | 14,012,000 |
| Net Income Prior Year | 90,954,000 |
| Quarterly Revenue Growth YOY | 17.80% |
| 5-Year Revenue Growth | 16.89% |
| Operating Margin Twelve Trailing Months | 13.80% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 321,029,000 |
| Total Cash Past Year | 324,404,000 |
| Total Cash Prior Year | 167,486,000 |
| Net Cash Position Most Recent Quarter | 321,029,000 |
| Net Cash Position Past Year | 324,404,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 1,150,931,000 |
| Total Stockholder Equity Prior Year | 1,178,944,000 |
| Total Stockholder Equity Most Recent Quarter | 1,358,696,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 152,621,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 3.90 |
| Free Cash Flow Past Year | 147,299,000 |
| Free Cash Flow Prior Year | 82,120,000 |
Options |
|
| Put/Call Ratio | 0.11 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 9.49 |
| MACD Signal | 9.60 |
| 20-Day Bollinger Lower Band | 224.40 |
| 20-Day Bollinger Middle Band | 261.93 |
| 20-Day Bollinger Upper Band | 299.47 |
| Beta | 0.66 |
| RSI | 58.10 |
| 50-Day SMA | 263.76 |
| 150-Day SMA | 248.49 |
| 200-Day SMA | 231.71 |
System |
|
| Modified | 12/9/2025 7:02:14 AM EST |